Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Protective Effects of Celastrol, the Triterpenoid Component of Celastrus Orbiculatus, on Dopaminergic Neuronal Cells in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned Parkinson's Disease Rats

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2008, v.29 no.4, pp.94-103



  • Downloaded
  • Viewed

Abstract

Objectives: The aim of this study was to determine whether celastrol, the triterpenoid component of Celastrus orbiculatus, offers neuroprotection against Parkinson's disease (PD) in mice administered 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine(MPTP). Methods: We examined how celastrol affected MPTP-induced neuronal loss of tyrosine hydroxylase (TH)-positive dopaminergic neurons in substantia nigra pars compacta (SNpc) in the midbrain of mice. C57BL/6J mice were divided into four groups: (1) saline-saline, (2) saline-celastrol, (3) MPTP-saline, and (4) MPTP-celastrol. The mice were injected intraperitoneally (i.p.) with four administrations of MPTP (18㎎/㎏) at 2 h intervals and then i.p. administered celastrol (3㎎/㎏) two times at 12 h after last celastrol administration. Expression of TH on the SNpc of brain tissues were analyzed at 7 days after the treatments by immunohistochemistry and Western blot. Results: Immunohistochemical analysis using TH antibody showed that celastrol provided significantly protective effects against MPTP-induced loss of TH-positive dopaminergic neurons in the SNpc region of the midbrain of mice. Our Western blot study also showed that celastrol significantly inhibits the MPTP-induced neuronal damage via the up-regulation of TH protein levels in MPTP mice. Conclusions: The present results suggest that it may be possible to use celastrol for the prevention of nigral degenerative disorders including PD, caused by exposure to toxic substances.

keywords
Celastrus orbiculatus, celastrol, dopaminergic neuron, neuroprotection, Parkinson's disease.


Reference

1

1. 서순규, 成人病 老人病學, 서울, 고려의학, 1992; 37-49, 77-83, 107-122, 137-139, 142-149.

2

2. Pappolla M, Omar R, Kim K, Robakis. Immun- ohistochemical evidence of oxidative stress in Alzheimer disease. Am. J. Pathol. 1992;140:621 -628.

3

3. Sendtner M, Thoenen H. Neurodegenerative disease. Oxidative stress and motorneuron disease. Curr. Biol. 1994;4:1036-1039.

4

4. Jenner P, Olanow C. Understanding cell death in Parkinson’s disease. Ann. Neurol. 1998;3:S72 -S84.

5

5. Smith PF. Inflammation in Parkinson’s disease: An update. Curr Opin Investig Drugs. 2008;9 (5):478-84.

6

6. Camins A, Pallas M, Silvestre JS. Apoptotic mechanisms involved in neurodegenerative dise- ases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol. 2008;30 (1):43-65.

7

7. McGeer PL, McGeer EG. Glial reactions in Parkinson’s disease.Mov Disord. 2008;23(4): 474-83.

8

8. Rock RB, Peterson PK. Microglia as a phar- macological target in infectious and inflam- matory diseases of the brain. J Neuroimmune Pharmacol. 2006;1(2):117-26.

9

9. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R. Inflammation in Parki- nson’s diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des. 2007;13(18):1925-8.

10

10. Lee P, Hur J, Lee J, Kim J, Jeong J, Kang I, Kim SY, Kim H. 15,16-dihydrotan shinone I suppresses the activation of BV-2 cell, a murine microglia cell line, by lipopolysaccharide. Neur- ochem Int. 2006;48:60-6.

11

11. Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neuro- signals. 2005;14:71-82.

12

12. Liu HQ, Zhang WY, Luo XT, Ye Y, Zhu XZ. Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease by activation of adenosine A1 receptor. Br J Pharmacol. 2006; 148:314-25.

13

13. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol. 2003;30 :399-404.

14

14. Yoon Y, Kim KS, Hong SG, Kang BJ, Lee MY, Cho DW. Protective effects of Orostachys japo- nicus A. Berger (Crassulaceae) on H2O2-induced apoptosis in GT1-1 mouse hypothalamic neur- onal cell line. J Ethnopharmacol. 2000;69:73-8.

15

15. 고동균. 유자가 lipopolysaccharide의 뇌실주입으로 유발된 생쥐의 혈중 IL-6와 TNF-a 변화에 미치는 영향. 대한한의학 방제학회지 2004;12:195 -208.

16

16. MJ Kim, MO Shin. The effects of growth inhibition and quinone reductase activity stimul- ation of Celastrus orbiculatus fractions in various cancer cells. The Kor. Nutrition 2007; 40(6): 493-499.

17

17. K.R. Kirtikar and B.D. Basu, Indian medicinal plants vol. 1, International Book Distributors, Dehradun (1987), p. 574.

18

18. Rajkumar R, Kumar EP, Sudha S, Suresh B. Evaluation of anxiolytic potential of Celastrus oil in rat models of behaviour. Fitoterapia. 2007; 78(2):120-4.

19

19. Kurata J, Nakao S, Murakawa M, Adachi T, Shichino T, Mori K. The cerebral cortex origin of enflurane-induced generalized seizure in cats.Anesth Analg. 1994;79(4):713-8.

20

20. Jin HZ, Hwang BY, Kim HS, Lee JH, Kim YH, Lee JJ. Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production. J Nat Prod. 2002;65(1):89-91.

21

21. Hwang BY, Kim HS, Lee JH, Hong YS, Ro JS, Lee KS, Lee JJ. Antioxidant benzoylated flavan- 3-ol glycoside from Celastrus orbiculatus. J Nat Prod. 2001;64(1):82-4.

22

22. Jung HW, Chung YS, Kim YS, Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med. 2007; 39(6):715-21.

23

23. Cleren C, Calingasan NY, Chen J, Beal MF. Celastrol protects against MPTP- and 3-nitropro- pionic acid-induced neurotoxicity. J Neurochem. 2005;94(4):995-1004.

24

24. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog Neuropsychop- harmacol Biol Psychiatry. 2001;25(7):1341-57.

25

25. Jossan G, Sakurai E, Oreland L. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol Toxicol. 1989;64:314-318.

26

26. Schapira AH. Progress in neuroprotection in Parkinson’s disease. Eur J Neurol. 2008;15:5-13.

27

27. Stoessl J. Potential therapeutic targets for Parkin- son’s disease. Expert Opin Ther Targets. 2008 ;12(4):425-36. (685)

28

28. Van Kampen J, Robertson H, Hagg T, Drobitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson’s disease. Exp Neurol. 2003;184(1):521-9.

29

29. Cao F, Sun S, Tong ET. Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats. J Huazhong Univ Sci Technolog Med Sci. 2003;23(2):151-3.

30

30. Li FQ, Cheng XX, Liang XB, Wang XH, Xue B, He QH, Wang XM, Han JS. Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp Neurol. 2003;179(1):28-37.

31

31. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 2006;545(1):51-64.

32

32. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006;72(10):1311-21.

33

33. Wang KW. A new fatty acid ester of triterpenoid from Celastrus rosthornianus with anti-tumor activitives. Nat Prod Res. 2007;21(7):669-74.

34

34. Mandel S, Grünblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strat- egies in Parkinson’s disease : an update on progress. CNS Drugs. 2003;17(10):729-62.

  • Downloaded
  • Viewed
  • 0KCI Citations
  • 0WOS Citations

Other articles from this issue

Recommanded Articles

상단으로 이동

Journal of Korean Medicine